Navigation Links
Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
Date:4/29/2009

CHICAGO, ILSipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.

Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded the pre-specified level of statistical significance defined by the study's design and reduced the overall risk of death by 22.5 percent compared to placebo (p-value=0.032). More than 500 patients were enrolled in the IMPACT trial, a multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent prostate cancer. The primary endpoint was overall survival.

Researchers are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo.

"The ability to boost survival for patients is the gold standard endpoint in prostate cancer clinical trials," said AUA spokesperson Ira D. Sharlip, MD. "The ability to give these patients both increased survival and possibly, improved quality of life, is very important."

Sipuleucel-T is an investigational therapy for men with androgen-independent prostate cancer. It is an active cellular immunotherapy designed to use live human cells to boost a patient's immune system to elicit a long-lasting response against cancer.


'/>"/>

Contact: Wendy Isett
wisett@auanet.org
410-977-4770
American Urological Association
Source:Eurekalert

Page: 1

Related medicine news :

1. Statins alter prostate cancer patients PSA levels
2. Living and Loving with Prostate Cancer: Men Deserve Better
3. Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
4. AUA Counters Mainstream Recommendations with New Best Practice Statement on Prostate-Specific Antigen Testing
5. Heart, Bone Problems May Follow Prostate Cancer Treatment
6. Prostate Study Shows BOTOX May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia
7. Prostate cancer therapy increases risk of fractures and cardiovascular-related death
8. Statins Guard Against Prostate Cancer
9. Statins may exert influence on prostate cancer growth by reducing inflammation
10. Major statin study reveals several important findings for reducing prostate cancer and disease
11. Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , ... begin franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation ... meditation mainstream. Current Meditation will be the first meditation concept in the U.S. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and ... children with autism spectrum disorder (ASD) to see films in an environment that ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... CALNOC, ... FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – ... the chairman and CEO of the Virginia Mason Health System in Seattle since 2000. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Urinary Incontinence ... and benchmarks in the global Urinary Incontinence market. The research ... the key drugs marketed for Urinary Incontinence and their clinical attributes? ...
(Date:2/23/2017)...  Genesis Healthcare Services has merged with Hospice Cloud, ... Bill Monast , President and CEO of Hospice ... Feltman , executives with Home Health Depot, Inc., the ... This acquisition helps Hospice Cloud maintain its position ... medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: